ETFs Investing in USANA Health Sciences, Inc. Stocks
This article lists various ETFs that include USANA Health Sciences, Inc. (USJ) stock in their portfolios. It provides a detailed table of 26 such funds, including their market value, weight of USJ stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs listed range from broad market funds to more specialized small-cap, value, and sector-specific funds.
1,205,587 Shares in USANA Health Sciences, Inc. $USNA Bought by Pzena Investment Management LLC
Pzena Investment Management LLC has acquired 1.21 million shares of USANA Health Sciences (NYSE:USNA) worth approximately $25.7 million, establishing a 6.53% stake in the company. This comes as USANA Health Sciences faces negative analyst sentiment, including "Sell" ratings, recent downgrades, and insider selling activity totaling $261,441 in the past 90 days. The company's shares opened near their 12-month low after missing analyst expectations for its quarterly earnings and revenue.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences (NYSE: USNA) has launched its Clear Protein + Creatine Mix, a new 3-in-1 active nutrition drink combining clear whey protein isolate, micronized creatine monohydrate, and electrolytes. Each 50-calorie serving provides 10g of protein, 5g of creatine, and over 600mg of electrolytes, designed for adults with active lifestyles seeking a simpler and lighter alternative to traditional protein shakes. The product is available in Twisted Citrus and Green Apple flavors and is manufactured in an FDA-registered, GMP-certified facility.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences has launched its new Clear Protein + Creatine Mix, a 3-in-1 drink designed to simplify daily nutrition for active adults. This single beverage combines 10g of clear whey protein isolate, 5g of micronized creatine monohydrate, and over 600mg of electrolytes in just 50 calories. The product aims to provide a convenient and refreshing alternative to consuming separate protein, creatine, and hydration supplements.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences has launched Clear Protein + Creatine Mix, a new 3-in-1 drink mix combining clear whey protein isolate, micronized creatine monohydrate, and electrolytes. Designed for active adults, each 50-calorie serving provides 10g of protein, 5g of creatine, and over 600mg of electrolytes, simplifying daily nutrition routines. The product is available in Twisted Citrus and Green Apple flavors and is free from added sugar, artificial flavors, or colors.
USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
USANA Health Sciences (NYSE: USNA) has launched Clear Protein + Creatine Mix, a new 3-in-1 drink mix combining 10g of clear whey protein isolate, 5g of micronized creatine monohydrate, and over 600mg of electrolytes in a single 50-calorie serving. This product aims to simplify the daily routines of active adults by consolidating three common supplements into one refreshing, easy-to-mix beverage without artificial flavors or colors. Available in Twisted Citrus and Green Apple, it is designed for everyday performance and manufactured in an FDA-registered, GMP-certified facility.
Usana Health Sciences | 10-Q: Q2 2026 Earnings Report
This document is the Q2 2026 Earnings Report (10-Q filing) for Usana Health Sciences. It contains the complete financial and operational disclosures for the second quarter of 2026 as required by regulatory bodies.
USANA Health Sciences (USNA) sees Renaissance report 5.19% equity stake
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have disclosed a 5.19% equity stake in USANA Health Sciences Inc. As of June 30, 2026, these entities beneficially own 958,520 shares of USANA common stock, exercising sole voting and dispositive power. The filing, an amended Schedule 13G/A, indicates that certain funds managed by Renaissance Technologies LLC will receive dividends and proceeds from the sale of these securities.
USANA Health Sciences Q2 Earnings Call Highlights
USANA Health Sciences (NYSE: USNA) lowered its full-year outlook due to increased digital customer acquisition costs for its Hiya brand and a packaging issue with Rise Wellness, resulting in significant revenue and margin pressure. Despite these challenges, the core nutrition business performed as expected, showing momentum in mainland China and early recovery in North Asia. The company recorded a $29 million non-cash goodwill impairment related to Hiya but maintained strong financial flexibility with $169 million in cash and no debt.
USANA Health Sciences (NYSE:USNA) Rating Lowered to Strong Sell at Zacks Research
Zacks Research has downgraded USANA Health Sciences (NYSE:USNA) to a "strong sell" from "hold," contributing to a consensus "sell" rating for the stock. This follows USANA's recent quarterly report, where the company missed EPS and revenue estimates and issued a lower-than-expected FY2026 EPS guidance. Shares opened near their 52-week low, and insiders have sold a significant amount of stock recently.
USANA Health Sciences (NYSE:USNA) Cut to "Hold" at Wall Street Zen
USANA Health Sciences (NYSE:USNA) has been downgraded to a "Hold" rating by Wall Street Zen, adding to previous downgrades from other analysts, resulting in an overall consensus rating of "Reduce." This follows the company missing earnings expectations in its latest quarter, reporting an adjusted loss of $0.07 per share against an estimated $0.43, and revenue of $223.27 million against an expected $235 million. Shares opened near their 12-month low, and insiders have sold over $261,000 worth of stock recently.
USANA Health Sciences (USNA) Stock Sinks After Hiya Impairment And Loss Shock
USANA Health Sciences (USNA) experienced a significant stock drop of 34.2% after reporting a Q2 2026 loss per share of US$1.16 on revenue of US$223.3m, compounded by a US$29m non-cash goodwill impairment related to its Hiya brand. The company swung from a profit of US$9.7m in Q2 2025 to a loss of US$21.4m in Q2 2026, raising concerns about its profit quality and multi-brand expansion strategy despite a seemingly strong core nutritional business and balance sheet.
USANA Health Sciences (USNA) Stock Sinks After Hiya Impairment And Loss Shock
USANA Health Sciences (USNA) experienced a significant stock drop of 34.2% after reporting a Q2 loss of US$1.16 per share and a US$29m goodwill impairment related to its Hiya brand. The company's revenue declined by 5.3% year-over-year, and it swung from a profit to a substantial loss, raising concerns about its profit quality and multi-brand expansion strategy despite a strong balance sheet and core nutritional business.
USANA Health Sciences, Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
NULL
Should USANA Health Sciences (USNA) Revisit Its Valuation After Lowered Guidance And Q2 Loss?
USANA Health Sciences (USNA) experienced a significant share price drop and reported a Q2 2026 net loss, lowered full-year guidance, and a $29 million goodwill impairment. Despite these setbacks, Simply Wall St's analysis suggests the stock is undervalued with a Price-to-Sales ratio of 0.3x compared to peers and an estimated fair value of $43.64 per share based on its DCF model. Investors are advised to review the underlying data and potential risks, although the current valuation implies a substantial discount.
Earnings call transcript: USANA Health Sciences posts Q2 2026 loss, stock sinks 28%
USANA Health Sciences (USNA) reported a significant Q2 2026 loss of 7 cents per share on $223 million revenue, widely missing analyst expectations, leading to a 28% stock decline. The loss was attributed to a non-cash goodwill impairment for its Hiya unit, a packaging issue with Rise Wellness, and a challenging digital advertising environment. Despite these setbacks, the company emphasized the stability of its core nutritional business, renewed momentum in Greater China, and a strong balance sheet with $169 million in cash and no debt.
Why USANA (USNA) Stock Is Nosediving
Shares of USANA Health Sciences (USNA) dropped significantly after the company reported second-quarter 2026 results that missed Wall Street's revenue and earnings expectations, posting an adjusted loss per share against forecasts for a profit. This steep decline overshadowed the reaffirmation of its full-year revenue guidance and a recent partnership renewal with Nordiq Canada. The company's stock has been volatile and is down 18.2% since the beginning of the year.
USANA Reports Q2 2026 Financial Results
USANA Health Sciences, Inc. announced its Q2 2026 financial results, with net sales of $223 million and a net loss of $21.4 million. The company experienced mixed performance, with its Core Nutritional business meeting expectations but its ventures, Hiya and Rise Wellness, performing below expectations due to digital marketing challenges and packaging disruptions. Despite these setbacks, USANA remains confident in its strategic transformation to a diversified omnichannel health and wellness company and plans to evolve its Brand Partner incentive plan, accelerate product innovation, and modernize technology for long-term growth.
USANA Chairman, CEO Kevin Guest Shares 5 Ways to Make Happiness Happen at Work and Home This August
Kevin Guest, Chairman and CEO of USANA Health Sciences, offers five practical tips to cultivate happiness during August's Happiness Happens Month. These tips include noticing existing good, creating moments of joy, recognizing others, helping without being asked, and protecting time for important people and priorities. Guest emphasizes that happiness is a choice and a practice that enhances both work and personal life.
USANA CEO's Parents Bought a Piano Before a Car—They Still Own It
USANA Health Sciences CEO Kevin Guest shares five happiness tips for both work and home to celebrate Happiness Happens Month in August. He emphasizes intentionally noticing good things, creating joyful moments, recognizing others, helping without being asked, and protecting time for important relationships. Guest relates these tips to his "Piano Principle," encouraging people to actively make space for what truly matters in their lives.
Lazard Asset Management LLC Invests $1.26 Million in USANA Health Sciences, Inc. $USNA
Lazard Asset Management LLC has acquired a new stake of 72,395 shares in USANA Health Sciences, Inc. (NYSE:USNA) worth approximately $1.26 million. This investment gives Lazard Asset Management a 0.39% stake in the company, where institutional investors and hedge funds collectively own 54.25%. USANA Health Sciences recently reported a quarterly loss and missed revenue expectations, and analyst sentiment remains negative with a consensus "Reduce" rating.
USANA Updates 2026 Sales Outlook After Hiya, Rise Fall Short
USANA Health Sciences reported a Q2 2026 net loss of $(21.4) million, including a $29.1 million impairment charge, and updated its fiscal year 2026 sales outlook downward due to underperformance in its Hiya and Rise Wellness ventures. The company's core nutritional business performed as expected, but Hiya faced digital marketing challenges and Rise Wellness experienced a packaging disruption. Despite these setbacks, USANA remains confident in its long-term strategy to diversify into an omnichannel health and wellness company.
USANA Health Sciences (USNA) Reports Q2 Loss, Lags Revenue Estimates
USANA Health Sciences (USNA) reported a Q2 loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.43, and revenues of $223.27 million, falling short of the $235.85 million reported a year ago. Despite outperforming the market year-to-date with a 16.4% stock gain, the company's current Zacks Rank is #3 (Hold), indicating that its shares are expected to perform in line with the market. Investors are now awaiting management's commentary on the earnings call to gauge future stock movement.
USANA Health Sciences Reports Second Quarter 2026 Results
USANA Health Sciences reported mixed Q2 2026 results, with consolidated net sales of $223 million and a net loss of $(21.4) million, including a $29.1 million impairment charge. The Core Nutritional business met expectations, but Hiya and Rise Wellness performed below forecasts, leading to updated fiscal year 2026 guidance with lower revenue and earnings projections. Despite these challenges, USANA remains committed to its strategy of transforming into a diversified, omnichannel health and wellness company.
USANA Health Sciences (NYSE:USNA) Posts Earnings Results, Misses Estimates By $0.50 EPS
USANA Health Sciences (NYSE:USNA) reported quarterly earnings, missing analyst estimates with a loss of $0.07 per share against a projected $0.43 profit, and revenue of $223.27 million, below the $235 million estimate. Shares traded up $0.05 to $22.89, giving the company a market capitalization of $422.53 million. Insider selling of 17,660 shares occurred, while institutional investors hold 54.25% of the stock, and analysts maintain a "Reduce" consensus rating despite one upgrade to "buy."
USANA Health Sciences (NYSE: USNA) swings to Q2 loss, trims 2026 forecast
USANA Health Sciences reported a Q2 2026 net loss of $(21.4) million, a significant swing from a net gain of $9.7 million in the prior year, primarily due to a $29.1 million goodwill impairment charge related to its Hiya reporting unit. The company also reduced its fiscal 2026 outlook, forecasting lower consolidated net sales and a net loss, citing challenges in Hiya's digital marketing and a packaging disruption for Rise Wellness. Despite these setbacks, USANA maintains a strong balance sheet with $169 million in cash and no debt, and remains confident in its long-term strategy to evolve into a diversified health and wellness company.
Earnings To Watch: USANA (USNA) Reports Q2 Results Tomorrow
USANA Health Sciences (USNA) is set to report its Q2 earnings this Tuesday. The market expects flat year-on-year revenue, a slowdown from last year's 10.8% increase, despite analysts reconfirming estimates. The company has a history of missing Wall Street's revenue estimates multiple times over the last two years, contrasting with some consumer staples peers who recently reported strong revenue growth.
USANA Health Sciences, Inc. Revenue Breakdown – NYSE:USNA
USANA Health Sciences, Inc. (NYSE: USNA) reported total revenue of $925.26 million USD last year. The Core Nutritional segment was the top performer, generating $775.45 million USD, while China was the largest regional contributor with $381.82 million USD in revenue.
Glow-Promoting Cellular Nutrition Formulas
USANA Health Sciences has shared the results of a 12-week consumer trial for its skincare supplement, Glow, which is designed to promote healthy and radiant skin from within. The study showed that over 97% of participants experienced improvements in skin brightness, radiance, and evenness, with more than 80% also noting better hydration, firmness, and elasticity. Glow's formula includes Damasty (rose extract, bioactive melon superoxide dismutase, acerola cherry vitamin C), astaxanthin, and grape seed oil, tapping into the growing trend of ingestible skincare and evidence-backed beauty products.
New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
USANA Health Sciences announced the results of a 12-week consumer study for its skincare supplement, Glow, showing significant improvements in participants' skin. The study, involving 36 individuals in the U.S. and Mexico, reported high percentages of brighter-looking, more radiant, and even-toned skin, along with improved hydration, firmness, and elasticity. These findings underscore USANA's philosophy of internal nutrition for external beauty, backed by the science of its Damasty®-infused formula.
New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
USANA Health Sciences announced the results of a 12-week consumer study on its skincare supplement, Glow, showing significant improvements in skin appearance. Participants reported brighter, more radiant, and even-toned skin, along with improved hydration, firmness, and elasticity. The study, conducted across the United States and Mexico, highlights the product's effectiveness in supporting healthy skin from within.
Glow-Promoting Cellular Nutrition Formulas
USANA Health Sciences has introduced Glow, a cellular nutrition supplement designed to promote healthy, radiant skin. A 12-week consumer trial involving 36 participants showed that over 97% experienced improvements in brightness and skin tone, with significant gains in hydration, firmness, and elasticity. The product's formulation includes Damasty, astaxanthin, and grape seed oil, tapping into growing trends in ingestible and clinically validated skincare.
New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow
USANA Health Sciences announced the results of a 12-week consumer study on its skincare supplement, Glow, revealing significant improvements in skin appearance. Participants reported enhanced brightness, radiance, and more even skin tone, with high percentages also noting better hydration, firmness, and elasticity. The study highlights USANA's commitment to science-backed products that deliver visible benefits for healthy skin from within.
USANA Health Sciences Number of Employees 2026 | Employee Count & Headcount Data
USANA Health Sciences (USNA) had 1,580 employees worldwide as of March 2026, marking a 4.6% decline from 2023. The company's workforce is primarily concentrated in the United States, Philippines, and Canada, with Mexico being its fastest-growing location. USANA is actively hiring, though job postings have significantly decreased, and employee sentiment is neutral but declining.
USANA Health Sciences Inc (USNA) Financial Health: Profitability & Balance Sheet Analysis
USANA Health Sciences Inc (USNA) currently boasts a robust financial score of 8.24, ranking 12th in the Food & Tobacco industry. The company reported a quarterly revenue of $250.22 million, showing a 0.27% year-over-year increase, and a significant 20.07% year-over-year increase in net profit. However, several specific financial data points like cash and cash equivalents, total assets, total liabilities, and free cash flow have not yet been disclosed by the company.
How Usana Health Sciences Inc. (USNA) Affects Rotational Strategy Timing
This article analyzes Usana Health Sciences Inc. (USNA) using AI models to determine its effect on rotational strategy timing. It identifies near-term weak sentiment, no clear price positioning, and offers institutional trading strategies including long, momentum breakout, and short positions. The analysis also provides multi-timeframe signal analysis tables for various holding periods.
How Usana Health Sciences Inc. (USNA) Affects Rotational Strategy Timing
This article analyzes Usana Health Sciences Inc. (USNA) with a focus on its impact on rotational trading strategies. Key findings indicate near-term weak sentiment that may resume long-term weakness after a neutral shift, with no clear price positioning signal and compelling upside potential due to a lack of resistance levels above the current price. The article provides specific institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis.
USANA Health Sciences (USNA) to Announce Earnings on Tuesday
USANA Health Sciences (NYSE:USNA) is scheduled to announce its Q2 2026 earnings on Tuesday, August 4th, with analysts expecting $0.43 EPS on $235.0 million in revenue. This follows a strong previous quarter where the company surpassed estimates with $0.61 EPS and $250.22 million in revenue. Despite recent insider selling activity, the stock saw a 4.7% increase, and institutional investors have been adjusting their positions.
USANA Health Sciences CIO Benedict Peter Increases Stock Holdings via RSU Vesting and Market Sale
USANA Health Sciences CIO Benedict Peter increased his stock holdings on July 25, 2026, through a combination of restricted stock unit vesting and open market transactions. This move, disclosed on July 27, 2026, demonstrates executive confidence in the nutritional supplement and wellness company (NYSE: USNA). The transactions provide insights into the company's executive compensation structure and insider sentiment towards the firm.
USANA Health Sciences Inc (USNA) Cash Flow
This article provides a detailed historical cash flow statement for USANA Health Sciences Inc (USNA), offering both quarterly and annual data for operating, investing, and financing activities through FY2026Q1. It also includes definitions and explanations of key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with USNA-specific figures for recent periods. Investors can use this data to assess the company's financial health and stability.
Form 4 USANA Health Sciences Inc For: 27 July By Investing.com
This article reports on a Form 4 filing for USANA Health Sciences Inc. on July 27. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article provides the title and date of the filing without further details.
Form 4 USANA Health Sciences Inc For: 27 July By Investing.com
This article announces the filing of Form 4 for USANA Health Sciences Inc. on July 27. It is a brief news item indicating a regulatory filing has occurred for the company.
USANA Health Sciences Director Nixon J. Scott Acquires 1,632 Restricted Stock Units, Signaling Confidence
USANA Health Sciences Director Nixon J. Scott recently acquired 1,632 restricted stock units on July 23, 2026. This transaction is seen as a potential signal of confidence in the company's future performance and governance. The acquisition has drawn investor interest, prompting speculation on its implications for the nutritional supplements market player.
USANA Health Sciences Inc (USNA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of USANA Health Sciences Inc (USNA) shareholder structure, listing major shareholders by proportion and categorizing shareholder types. It also includes institutional shareholding trends over several quarters and recent shareholder activity with changes in holdings for key investors. Additionally, it lists several ETFs that include USNA in their portfolios.
USANA Health Sciences Inc (USNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for USANA Health Sciences Inc (USNA) by business segment and geographical region. As of April 6, FY2025, the company's revenue is primarily driven by USANA® Nutritionals and includes contributions from USANA Foods, Personal care and Skincare, Hiya nutritional supplements, and other categories. Regionally, Greater China accounts for the largest proportion of revenue, followed by Americas and Europe, Southeast Asia Pacific, and North Asia.
USNA|USANA Health Sciences Inc|Price:21.320|Chg%:+0.400
This article provides a financial overview of USANA Health Sciences Inc. (USNA), including its stock performance, market capitalization, P/E ratio, and upcoming earnings date. It details key financial indicators such as EPS, revenue, net profit, net margin, gross margin, and debt-to-asset ratio across various quarters and fiscal years. The article also includes FAQs covering the company's total revenue, assets, liabilities, equity, net operating income, net investment, net financing, EPS, net income, and various margin and return ratios for FY2025.
USANA Health Sciences Inc USNA Balance Sheet
This article provides a detailed historical balance sheet for USANA Health Sciences Inc (USNA), offering quarterly and annual financial data. It allows users to evaluate the company's financial health, analyze fundamentals, and calculate key ratios related to liquidity, leverage, and return on equity. The content includes a comprehensive breakdown of assets, liabilities, and shareholders' equity over multiple fiscal years, along with an FAQ section clarifying important financial metrics and definitions.
USANA Health Sciences Inc (USNA) Institutional Confidence
The article analyzes the institutional confidence score for USANA Health Sciences Inc (USNA), which currently stands at 5.00, ranking it 39th out of 93 in the Food & Tobacco industry. The latest institutional shareholding proportion is 61.48%, marking a quarter-over-quarter increase of 2.68%. Richard Pzena is identified as the largest institutional shareholder, holding 1.03 million shares, representing 6.01% of shares outstanding.
USANA Health Sciences Renews Four-Year Partnership with Nordiq Canada,
USANA Health Sciences has renewed its partnership with Nordiq Canada for another four years, extending through the 2030 Olympic Winter Games. As the official nutritional product supplier, USANA will provide its NSF Certified for Sport® products to support Nordiq Canada's elite cross-country ski athletes. This collaboration emphasizes both organizations' commitment to athlete well-being, clean sport, and peak performance, with Nordiq Canada CEO Beckie Scott highlighting the importance of partners who uphold values of integrity and fair play.
USANA Renews Partnership with Nordiq Canada
USANA Health Sciences has renewed its partnership with Nordiq Canada, continuing as the official nutrition partner for the Canadian cross-country skiing national governing body. This agreement ensures that USANA will supply NSF Certified for Sport nutritional products to Nordiq Canada’s elite athletes through to the 2030 Olympic Winter Games and beyond. Both organizations emphasize their shared commitment to athlete health, integrity, and clean sport, with USANA strengthening its presence in the Canadian market through this collaboration.
